197 related articles for article (PubMed ID: 17161059)
1. Chronic inotropic therapy in end-stage heart failure.
Hauptman PJ; Mikolajczak P; George A; Mohr CJ; Hoover R; Swindle J; Schnitzler MA
Am Heart J; 2006 Dec; 152(6):1096.e1-8. PubMed ID: 17161059
[TBL] [Abstract][Full Text] [Related]
2. Outpatient parenteral inotropic therapy for advanced heart failure.
Young JB; Moen EK
J Heart Lung Transplant; 2000 Aug; 19(8 Suppl):S49-57. PubMed ID: 11016488
[TBL] [Abstract][Full Text] [Related]
3. Prognosis on chronic dobutamine or milrinone infusions for stage D heart failure.
Gorodeski EZ; Chu EC; Reese JR; Shishehbor MH; Hsich E; Starling RC
Circ Heart Fail; 2009 Jul; 2(4):320-4. PubMed ID: 19808355
[TBL] [Abstract][Full Text] [Related]
4. Need for hospice and palliative care services in patients with end-stage heart failure treated with intermittent infusion of inotropes.
López-Candales AL; Carron C; Schwartz J
Clin Cardiol; 2004 Jan; 27(1):23-8. PubMed ID: 14743852
[TBL] [Abstract][Full Text] [Related]
5. Intermittent inotropic therapy in an outpatient setting: a cost-effective therapeutic modality in patients with refractory heart failure.
Marius-Nunez AL; Heaney L; Fernandez RN; Clark WA; Ranganini A; Silber E; Denes P
Am Heart J; 1996 Oct; 132(4):805-8. PubMed ID: 8831370
[TBL] [Abstract][Full Text] [Related]
6. Outcomes associated with vasoactive therapy in patients with acute decompensated heart failure.
Arnold LM; Crouch MA; Carroll NV; Oinonen MJ
Pharmacotherapy; 2006 Aug; 26(8):1078-85. PubMed ID: 16863484
[TBL] [Abstract][Full Text] [Related]
7. Continuous Cardiac Inotropes in Patients With End-Stage Heart Failure: An Evolving Experience.
Malotte K; Saguros A; Groninger H
J Pain Symptom Manage; 2018 Jan; 55(1):159-163. PubMed ID: 29030210
[TBL] [Abstract][Full Text] [Related]
8. Effects of intravenous home dobutamine in palliative end-stage heart failure on quality of life, heart failure hospitalization, and cost expenditure.
Martens P; Vercammen J; Ceyssens W; Jacobs L; Luwel E; Van Aerde H; Potargent P; Renaers M; Dupont M; Mullens W
ESC Heart Fail; 2018 Aug; 5(4):562-569. PubMed ID: 29341466
[TBL] [Abstract][Full Text] [Related]
9. Comparison of dobutamine versus milrinone therapy in hospitalized patients awaiting cardiac transplantation: a prospective, randomized trial.
Aranda JM; Schofield RS; Pauly DF; Cleeton TS; Walker TC; Monroe VS; Leach D; Lopez LM; Hill JA
Am Heart J; 2003 Feb; 145(2):324-9. PubMed ID: 12595851
[TBL] [Abstract][Full Text] [Related]
10. Home inotropic therapy in children.
Berg AM; Snell L; Mahle WT
J Heart Lung Transplant; 2007 May; 26(5):453-7. PubMed ID: 17449413
[TBL] [Abstract][Full Text] [Related]
11. Hospital variation in intravenous inotrope use for patients hospitalized with heart failure: insights from Get With The Guidelines.
Allen LA; Fonarow GC; Grau-Sepulveda MV; Hernandez AF; Peterson PN; Partovian C; Li SX; Heidenreich PA; Bhatt DL; Peterson ED; Krumholz HM;
Circ Heart Fail; 2014 Mar; 7(2):251-60. PubMed ID: 24488983
[TBL] [Abstract][Full Text] [Related]
12. Comparison of Positive Inotropic Agents in the Management of Acute Decompensated Heart Failure.
Kelly J; Cheng J; Malloy R; Lupi K
J Cardiovasc Pharmacol; 2020 May; 75(5):455-459. PubMed ID: 32091426
[TBL] [Abstract][Full Text] [Related]
13. Home inotropic therapy in advanced heart failure: cost analysis and clinical outcomes.
Harjai KJ; Mehra MR; Ventura HO; Lapeyre YM; Murgo JP; Stapleton DD; Smart FW
Chest; 1997 Nov; 112(5):1298-303. PubMed ID: 9367472
[TBL] [Abstract][Full Text] [Related]
14. Symptomatic improvement in patients treated with intermittent infusion of inotropes: a double-blind placebo controled pilot study.
López-Candales A; Vora T; Gibbons W; Carron C; Simmons P; Schwartz J
J Med; 2002; 33(1-4):129-46. PubMed ID: 12939113
[TBL] [Abstract][Full Text] [Related]
15. Outpatient continuous inotrope infusion as an adjunct to heart failure therapy in Duchenne muscular dystrophy.
Cripe LH; Barber BJ; Spicer RL; Wong BL; Weidner N; Benson DW; Markham LW
Neuromuscul Disord; 2006 Nov; 16(11):745-8. PubMed ID: 17005398
[TBL] [Abstract][Full Text] [Related]
16. Beneficial effects of intermittent home administration of the inotrope/vasodilator milrinone in patients with end-stage congestive heart failure: a preliminary study.
Cesario D; Clark J; Maisel A
Am Heart J; 1998 Jan; 135(1):121-9. PubMed ID: 9453531
[TBL] [Abstract][Full Text] [Related]
17. Comparison of dobutamine-based and milrinone-based therapy for advanced decompensated congestive heart failure: Hemodynamic efficacy, clinical outcome, and economic impact.
Yamani MH; Haji SA; Starling RC; Kelly L; Albert N; Knack DL; Young JB
Am Heart J; 2001 Dec; 142(6):998-1002. PubMed ID: 11717603
[TBL] [Abstract][Full Text] [Related]
18. Continuous home ambulatory intravenous inotropic drug therapy in severe heart failure: safety and cost efficacy.
Sindone AP; Keogh AM; Macdonald PS; McCosker CJ; Kaan AF
Am Heart J; 1997 Nov; 134(5 Pt 1):889-900. PubMed ID: 9398101
[TBL] [Abstract][Full Text] [Related]
19. Intermittent inotropes for advanced heart failure: inquiring minds want to know.
Silver MA
Am Heart J; 1999 Aug; 138(2 Pt 1):191-2. PubMed ID: 10426825
[No Abstract] [Full Text] [Related]
20. Effect of Inpatient Dobutamine versus Milrinone on Out-of-Hospital Mortality in Patients with Acute Decompensated Heart Failure.
King JB; Shah RU; Sainski-Nguyen A; Biskupiak J; Munger MA; Bress AP
Pharmacotherapy; 2017 Jun; 37(6):662-672. PubMed ID: 28475215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
